Business Context and Reporting Period
This Form 6-K filing by Mereo Biopharma Group Plc, dated May 21, 2019, serves as a notice of the Company's Annual General Meeting (AGM) scheduled for June 19, 2019. Mereo is a clinical-stage UK-based biopharmaceutical company focused on rare diseases. The filing does not contain financial results for a specific reporting period but outlines the company's strategic pipeline and corporate governance events.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As a clinical-stage company, the document focuses on operational milestones rather than financial performance metrics.
Material Changes and Pipeline Updates
- BPS-804 (Osteogenesis Imperfecta): Enrollment of 112 adult patients in a Phase 2b dose-ranging study was completed in October 2018. Initial data is expected in Q2 2019, with top-line data in late 2019. A pediatric Phase 3 study design has been approved by the EMA.
- MPH-966 (Alpha-1 Antitrypsin Deficiency): Dosing of the first patient in a U.S. Phase 2 dose-ranging study has commenced, with data expected around the end of 2019.
- BCT-197 (COPD): Following positive Phase 2 data in May 2018 and a successful Phase 2 Type B meeting with the FDA, the Company has outlined the pivotal Phase 3 study endpoints.
- BGS-649 (Hypogonadotropic Hypogonadism): Positive top-line Phase 2b data was announced in March 2018, followed by positive safety extension results in December 2018.
- Navicixizumab: Completed Phase 1a single-agent trials and recently completed enrollment for a Phase 1b combination trial in platinum-resistant ovarian cancer.
- Etigilimab: Completed Phase 1a trials and is currently in a Phase 1b combination study with nivolumab.
Outlook, Contingencies, and Management Commentary
Contingency Payment: Etigilimab is part of OncoMed's prior collaboration with Celgene. Celgene holds an option to obtain an exclusive license to develop and commercialize the product. If Celgene exercises this option, OncoMed (now a wholly-owned indirect subsidiary of Mereo) is eligible to receive a $35 million opt-in payment.
Corporate Governance: The Annual General Meeting will be held on June 19, 2019, at the Marlborough Theatre in London. A copy of the Notice of AGM is available on the Company's website.
Key Facts for Investor Verification
- Verify the expected timing of initial data for the BPS-804 Phase 2b study (Q2 2019).
- Monitor the status of Celgene's option exercise regarding Etigilimab to confirm the potential $35 million contingent payment.
- Confirm the progress of the BCT-197 pivotal Phase 3 study following the FDA Type B meeting.
- Review the full Notice of Annual General Meeting for details on shareholder proposals and director elections.